Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)
Price and Volume
Detailed Quote| Volume | 1,845,287 |
| Open | 109.70 |
| Bid (Size) | 107.22 (100) |
| Ask (Size) | 111.49 (500) |
| Prev. Close | 109.84 |
| Today's Range | 109.70 - 112.65 |
| 52wk Range | 61.23 - 116.84 |
| Shares Outstanding | 142,334,900 |
| Dividend Yield | N/A |
Top News
More NewsPerformance
52-Week Range
5.5% below 52-week high
110.42
61.2352W Low
116.8452W High
1 Week
3.1% below 1-week high
106.651W Low
114.001W High
Halozyme Therapeutics, Inc. - Common Stock (HALO) traded between $61.23 and $116.84 over the past 52 weeks and last traded at $110.42, 5.5% below its 52-week high. Over the past week it ranged between $106.65 and $114.00.
Past 12 Months
+0.5%
+1.9%
+40.4%
+64.6%
+57.0%
+69.4%
1W
+$0.56
1M
+$2.11
3M
+$31.80
6M
+$43.34
YTD
+$40.11
1Y
+$45.22
HALO was +69.4% over the past year, +64.6% over six months, +57.0% year to date, +0.5% in the last week.
12 Months vs Market
HALO
+69.4%
DIA
+10.7%
SPY
+15.7%
QQQ
+22.9%
IWM
+13.1%
Over the past 12 months HALO returned +69.4% versus DIA (Dow) +10.7%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +22.9% and IWM (Russell 2000) +13.1%.
Volume & Liquidity
0.85× 3-mo avg
Today 1,845,287
3-mo avg 2.2M
1W
2.2M
1M
2.5M
3M
2.2M
6M
2.0M
YTD
1.9M
1Y
2.0M
HALO most recently traded 1,845,287 shares against a 3-month average daily volume of 2.2M.
More News
Read More
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
September 24, 2026
Via StockStory
Topics
Artificial Intelligence
1 Cash-Producing Stock to Target This Week and 2 We Question
September 22, 2026
Via StockStory
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
August 31, 2026
Via StockStory
Topics
Fraud
3 Market-Beating Stocks for Long-Term Investors
August 28, 2026
Via StockStory
1 Healthcare Stock with Exciting Potential and 2 We Avoid
August 27, 2026
Via StockStory
Topics
Economy
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
August 24, 2026
Via StockStory
Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics
Earnings
Via StockStory
Via StockStory
Topics
Artificial Intelligence
1 Profitable Stock to Research Further and 2 We Ignore
August 07, 2026
Via StockStory
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics
Earnings
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
August 04, 2026
Via StockStory
3 Growth Stocks Set to Flourish
August 03, 2026
Via StockStory
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
July 24, 2026
Via StockStory
Topics
Energy
1 Value Stock Worth Investigating and 2 Facing Headwinds
July 15, 2026
Via StockStory
2 Reasons to Like HALO and 1 to Stay Skeptical
July 10, 2026
Via StockStory
Topics
Stocks
Frequently Asked Questions
Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 110.42
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 10/09/26 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 15.72B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 16B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>